Effect of denosumab for the treatment of postmenoposal osteoporosis in woman caused by the loss of ovarian function due to gynecologic malignancies
Not Applicable
Recruiting
- Conditions
- Osteoporosis
- Registration Number
- JPRN-UMIN000017279
- Lead Sponsor
- Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Patients are excluded if being 1. with concomitant use of other agents for osteoporosis 2. with concomitant use of other agents, which potentially affect bone turnover 3. with hypersensitivity to denosumab or other bisphosphonates 4. with hypocalcaemia 5. with severe nephropathy 6. with advanced or metastatic malignancy 7. inappropriate to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hip BMD and lumber BMD (DXA scan) Bone turnover markers (serum type I collagen cross-linked N-telopeptide)
- Secondary Outcome Measures
Name Time Method